<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput xmlns:ns2="local" id="104898" name="RVT-802"><HDS>Pre-registration</HDS><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation><RegulatoryDesignation id="17">Regenerative Medicine Advanced Therapy</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="59620" type="secondary">Unspecified drug target</Action><Action id="7761" type="secondary">T-lymphocyte stimulator</Action></Actions><Indications><Indication id="2668" type="primary">DiGeorge syndrome</Indication><Indication id="3623" type="primary">Severe combined immunodeficiency syndrome</Indication><Indication id="609" type="primary">Genetic disorder</Indication></Indications><Entities><Entity>Biological</Entity></Entities><OriginatorCompany id="20567">Duke University</OriginatorCompany></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput>